How Do Innate Immune Cells Contribute to Airway Remodeling in COPD Progression?

References

• MontesOM, Pérez-PadillaR. Global initiative for Chronic Obstructive Lung Disease (GOLD)-2017: the alat perspective. Arch Bronconeumol. 2017;53(3):87.28222935
   PubMed Web of Science ®Google Scholar
• DerekEB, KangyunW, GeoffreyDV, et al. Triggering receptor expressed on myeloid cells-2 expression tracks with M2-like macrophage activity and disease severity in COPD. Chest. 2015;153(1):77–86.
   Google Scholar
• BurgelPR, BourdinA, PiletteC, et al. Structural abnormalities and inflammation in COPD: a focus on small airways. Rev Mal Respir. 2011;28(6):749–760. doi:10.1016/j.rmr.2011.01.00921742236
   PubMed Web of Science ®Google Scholar
• PiniL, PinelliV, ModinaD, et al. Central airways remodeling in COPD patients. Int J Chron Obstruct Pulmon Dis. 2014;927–933. doi:10.2147/COPD.S5247825214779
   PubMed Web of Science ®Google Scholar
• ThoNV, RyujinY, OgawaE, et al. Relative contributions of emphysema and airway remodelling to airflow limitation in COPD: consistent results from two cohorts. Respirology. 2015;20(4):594–601. doi:10.1111/resp.1250525788016
   PubMed Web of Science ®Google Scholar
• ShimizuK, HasegawaM, MakitaH, et al. Comparison of airway remodeling assessed by computed tomography in asthma and COPD. Respir Med. 2011;105(9):1275–1283. doi:10.1016/j.rmed.2011.04.00721646007
   PubMed Web of Science ®Google Scholar
• DournesG, LaurentF, CosteF, et al. Computed tomographic measurement of airway remodeling and emphysema in advanced chronic obstructive pulmonary disease. Correlation with pulmonary hypertension. Am J Respir Crit Care Med. 2015;191(1):63. doi:10.1164/rccm.201408-1423OC25393421
   PubMed Web of Science ®Google Scholar
• HoggJC, TimensW. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4(1):435–459. doi:10.1146/annurev.pathol.4.110807.09214518954287
   PubMed Web of Science ®Google Scholar
• JonesRL, NoblePB, ElliotJG, et al. Airway remodelling in COPD: it’s not asthma. Respirology. 2016;21(8):1347–1356. doi:10.1111/resp.1284127381663
   PubMed Web of Science ®Google Scholar
• MichaeloudesC, KuoCH, HajiG, et al. Metabolic re-patterning in COPD airway smooth muscle cells. Eur Respir J. 2017;50(5):1700202. doi:10.1183/13993003.00202-201729191950
   PubMed Web of Science ®Google Scholar
• LimjunyawongN, CraigJM, LagasséHA, et al. Experimental progressive emphysema in BALB/cJ mice as a model for chronic alveolar destruction in humans. Am J Physiol Lung Cell Mol Physiol. 2015;309(7):L662–L676. doi:10.1152/ajplung.00214.201526232300
   PubMed Web of Science ®Google Scholar
• MccullaghBN, ComellasAP, BallasZK, et al. Antibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD). PLoS One. 2017;12(2):e0172437. doi:10.1371/journal.pone.017243728212436
   PubMed Web of Science ®Google Scholar
• MoisieievaNV, BuryaLV, KapustianskayaAA, et al. Comprehensive patterns of comorbidity: copd and depression. Aspects of treatment. Wiad Lek. 2018;71:588–591.29783230
   PubMedGoogle Scholar
• HoonhorstSJM, HackenNHTT, AdèleTLTL, et al. Lower Corticosteroid skin blanching response is associated with severe COPD. PLoS One. 2014;9(3):e91788. doi:10.1371/journal.pone.009178824622644
   PubMed Web of Science ®Google Scholar
• LöfdahlM, KaarteenahoR, Lappi-BlancoE, et al. Tenascin-C and alpha-smooth muscle actin positive cells are increased in the large airways in patients with COPD. Respir Res. 2011;12(15):48. doi:10.1186/1465-9921-12-4821496259
   PubMed Web of Science ®Google Scholar
• VictorK, MichelleO, HebaD, et al. Chronic bronchitis and current smoking are associated with more goblet cells in moderate to severe COPD and smokers without airflow obstruction. PLoS One. 2015;10(2):e0116108. doi:10.1371/journal.pone.011610825646735
   PubMed Web of Science ®Google Scholar
• AoshibaK, NagaiA. Differences in airway remodeling between asthma and chronic obstructive pulmonary disease. Clin Rev Allergy Immunol. 2004;27(1):35–43. doi:10.1385/CRIAI:27:115347849
   PubMed Web of Science ®Google Scholar
• RutgersSR, PostmaDS, TenHNHT, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 2000;55:12–18. doi:10.1136/thorax.55.1.1210607796
   PubMed Web of Science ®Google Scholar
• EapenMS, McalindenKD, TanD, et al. Inflammation paradox–a detailed analysis of inflammatory profile in the large and small airway wall in mild to moderate chronic obstructive pulmonary disease (COPD) patients. Eur Respir J. 2016;48:120.
   Google Scholar
• ZaniniA, SpanevelloA, BaraldoS, et al. Decreased maturation of dendritic cells in the central airways of COPD patients is associated with VEGF, TGF-β and vascularity. Respiration. 2014;87(3):234–242. doi:10.1159/00035674924435103
   PubMed Web of Science ®Google Scholar
• BirchJ, JohnsonG, JiwaK, et al. S65 Large and small airway epithelial cell senescence present in COPD and bronchiectasis. Thorax. 2013;68(Suppl 3):35. doi:10.1136/thoraxjnl-2013-204457.72
   Web of Science ®Google Scholar
• HoggJC, ChuF, UtokaparchS, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–2653. doi:10.1056/NEJMoa03215815215480
   PubMed Web of Science ®Google Scholar
• Abo-ZeidA, SabryI, HanyH. Effect of smoking cessation on airway inflammation in COPD. Egypt J Bronchol. 2013;7(1):13–20.
   Google Scholar
• EapenMS, HansbroPM, McalindenK, et al. Abnormal M1/M2 macrophage phenotype profiles in the small airway wall and lumen in smokers and chronic obstructive pulmonary disease (COPD). Sci Rep. 2017;7(1):13392. doi:10.1038/s41598-017-13888-x29042607
   PubMed Web of Science ®Google Scholar
• EltboliO, BafadhelM, HollinsF, et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med. 2014;14(1):1–10. doi:10.1186/1471-2466-14-11224387157
   PubMed Web of Science ®Google Scholar
• StefanoAD, CaramoriG, RicciardoloFLM, et al. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. Clin Exp Allergy. 2004;34(8):1156–1167. doi:10.1111/j.1365-2222.2004.02030.x15298554
   PubMed Web of Science ®Google Scholar
• StollP, UlrichM, BratkeK, et al. Imbalance of dendritic cell co-stimulation in COPD. Respir Res. 2015;16(1):19. doi:10.1186/s12931-015-0174-x25775429
   PubMed Web of Science ®Google Scholar
• MoriM, AnderssonCK, SvedbergKA, et al. Appearance of remodelled and dendritic cell-rich alveolar-lymphoid interfaces provides a structural basis for increased alveolar antigen uptake in chronic obstructive pulmonary disease. Thorax. 2013;68(6):521. doi:10.1136/thoraxjnl-2012-20287923412435
   PubMed Web of Science ®Google Scholar
• PaceE, FerraroM, MinerviniMI, et al. Innate immunity responses are differently altered in central and distal airways of COPD patients. American Thoracic Society 2009 International Conference; San Diego, California. May 15-20, 2009.
   Google Scholar
• PerotinJM, AdamD, Vella-BoucaudJ, et al. Delay of airway epithelial wound repair in COPD is associated with airflow obstruction severity. Respir Res. 2014;15(1):1–9. doi:10.1186/s12931-014-0151-924397246
   PubMed Web of Science ®Google Scholar
• ManzelLJ, ShiL, O’ShaughnessyPT, ThornePS, LookDC. Inhibition by cigarette smoke of nuclear factor-κB-dependent response to bacteria in the airway. Am J Respir Cell Mol Biol. 2011;44:155–165. doi:10.1165/rcmb.2009-0454OC20348206
   PubMed Web of Science ®Google Scholar
• SohalSS, EapenMS, WardC, et al. Epithelial mesenchymal transition (EMT): a necessary new therapeutic target in COPD? Am J Respir Crit Care Med. 2017;196(3):393. doi:10.1164/rccm.201704-0771LE28640653
   PubMed Web of Science ®Google Scholar
• GanesanS, SajjanUS. Repair and remodeling of airway epithelium after injury in Chronic Obstructive Pulmonary Disease. Respir Care. 2013;2(3):145–154.
   Google Scholar
• SaiedEM, BediwyAS. Expression of epidermal growth factor receptor (EGFR) in the bronchial epithelium of patients with chronic obstructive pulmonary disease (COPD). Eur Respir J. 2011;125(55):3823.
   Google Scholar
• MartinC, Frija-MassonJ, BurgelPR, et al. Targeting mucus hypersecretion: new therapeutic opportunities for COPD? Drugs. 2014;74(10):1073–1089. doi:10.1007/s40265-014-0235-324890395
   PubMed Web of Science ®Google Scholar
• PouwelsSD, HeijinkIH, HackenNHT, et al. DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol. 2014;7(2):215–226. doi:10.1038/mi.2013.7724150257
   PubMed Web of Science ®Google Scholar
• PouwelsSD, Van GeffenWH, JonkerMR, et al. Increased neutrophil expression of pattern recognition receptors during COPD exacerbations. Respirology. 2017;22(2):401–404. doi:10.1111/resp.1291227679416
   PubMed Web of Science ®Google Scholar
• KinoseD, OgawaE, KudoM, et al. Association of COPD exacerbation frequency with gene expression of pattern recognition receptors in inflammatory cells in induced sputum. Clin Respir J. 2016;10(1):11–21. doi:10.1111/crj.2016.10.issue-124902764
   PubMed Web of Science ®Google Scholar
• Halper-StrombergE, YunJH, ParkerMM, et al. Systemic markers of adaptive and innate immunity are associated with COPD severity and spirometric disease progression. Am J Respir Cell Mol Biol. 2018;58(4):500–509. doi:10.1165/rcmb.2017-0373OC29206476
   PubMed Web of Science ®Google Scholar
• FreemanCM, CurtisJL. Lung dendritic cells: shaping immune responses throughout chronic obstructive pulmonary disease progression. Am J Respir Cell Mol Biol. 2017;56(2):152.27767327
   PubMed Web of Science ®Google Scholar
• GiviME, RedegeldFA, FolkertsG, et al. Dendritic cells in pathogenesis of COPD. Curr Pharm Des. 2012;18(16):2329–2335. doi:10.2174/13816121280016606822390696
   PubMed Web of Science ®Google Scholar
• GiviME, FolkertsG, WagenaarGTM, et al. Cigarette smoke differentially modulates dendritic cell maturation and function in time. Respir Res. 2015;16(1):1–10. doi:10.1186/s12931-015-0291-625567521
   PubMedGoogle Scholar
• ShanM, ChengHF, SongLZ, et al. Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses in human emphysema. Sci Transl Med. 2009;1(4):4ra10. doi:10.1126/scitranlsmed.3000154
   PubMed Web of Science ®Google Scholar
• MaYJ. Correlation between small intestinal bacterial overgrowth and dendritic cell phenotype and function in cirrhotic patients with hepatitis B. World J Gastroenterol. 2016;24(3):443.
   Google Scholar
• BarnesPJ. Alveolar macrophages as orchestrators of COPD. COPD. 2004;1:59–70. doi:10.1081/COPD-12002870116997739
   PubMedGoogle Scholar
• StewartJI, CrinerGJ. The small airways in chronic obstructive pulmonary disease: pathology and effects on disease progression and survival. Curr Opin Pulm Med. 2013;19(2):109–115. doi:10.1097/MCP.0b013e32835ceefc23325030
   PubMed Web of Science ®Google Scholar
• StoutRD, SuttlesJ. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol. 2004;76(3):509–513. doi:10.1189/jlb.050427215218057
   PubMed Web of Science ®Google Scholar
• DewhurstJA, LeaS, HardakerE, et al. Characterisation of lung macrophage subpopulations in COPD patients and controls. Sci Rep. 2017;7(1):7143. doi:10.1038/s41598-017-07101-228769058
   PubMed Web of Science ®Google Scholar
• BerensonCS, KruzelRL, EberhardtE, et al. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. J Infect Dis. 2013;208(12):2036–2045. doi:10.1093/infdis/jit40023908477
   PubMed Web of Science ®Google Scholar
• EurlingsIM, DentenerMA, MerckenEM, et al. A comparative study of matrix remodeling in chronic models for COPD; mechanistic insights into the role of TNF-α. Am J Physiol Lung Cell Mol Physiol. 2014;307(7):557–565. doi:10.1152/ajplung.00116.2014
   PubMed Web of Science ®Google Scholar
• EurlingsIM, ReynaertNL, van de WeteringC, et al. Involvement of c-Jun N-terminal kinase in TNF-α-driven remodeling. Am J Respir Cell Mol Biol. 2017;56(3):393. doi:10.1165/rcmb.2015-0195OC27875656
   PubMed Web of Science ®Google Scholar
• PouwelsSD, Van GeffenWH, JonkerMR, et al. Increased neutrophil expression of pattern recognition receptors during COPD exacerbations. Respirology. 2016;22(2):401. doi:10.1111/resp.1291227679416
   PubMed Web of Science ®Google Scholar
• EllingsenJ, HedenströmH, HögmanM, et al. The relationship between blood neutrophils, blood eosinophils and exacerbations of COPD–results from the TIE-study. Eur Respir J. 2016;48(suppl 60):PA1013.
   Google Scholar
• StockleyRA. Neutrophils and the pathogenesis of COPD. Chest. 2002;121(5):151S–155S. doi:10.1378/chest.121.5_suppl.151S12010844
   PubMed Web of Science ®Google Scholar
• TulahAS, ParkerSG, MoffattMF, et al. The role of ALOX5AP, LTA4H and LTB4R polymorphisms in determining baseline lung function and COPD susceptibility in UK smokers. BMC Med Genet. 2011;12(1):173. doi:10.1186/1471-2350-12-17322206291
   PubMedGoogle Scholar
• SngJJ, PrazakovaS, ThomasPS, et al. MMP-8, MMP-9 and neutrophil elastase in peripheral blood and exhaled breath condensate in COPD. COPD. 2017;14(2):238–244. doi:10.1080/15412555.2016.124979027880043
   PubMedGoogle Scholar
• EchevarríaLU, LeimgruberC, GonzálezJG, et al. Evidence of eosinophil extracellular trap cell death in COPD: does it represent the trigger that switches on the disease? Int J Chron Obstruct Pulmon Dis. 2017;12:885–896. doi:10.2147/COPD28352169
   PubMed Web of Science ®Google Scholar
• KaurM, BeardsallM, SinghD TLR stimulation induces glucocorticoid insensitive production of functional neutrophil chemoattractant from COPD alveolar macrophages. American Thoracic Society 2011 International Conference Denver, Colorado; May 13-18, 2011.
   Google Scholar
• SinD, van EedenSF. Neutrophil-mediated lung damage: a new COPD phenotype? Respiration. 2012;83(2):103–105. doi:10.1159/00033417822142967
   PubMed Web of Science ®Google Scholar
• RijavecM, VolarevicS, OsolnikK, et al. Natural killer T cells in pulmonary disorders. Respir Med. 2011;105(supplement 1):S20. doi:10.1016/S0954-6111(11)70006-322015081
   PubMed Web of Science ®Google Scholar
• VijayanandP, SeumoisG, PickardC, et al. Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. N Engl J Med. 2007;356(14):1410–1422. doi:10.1056/NEJMoa06469117409322
   PubMed Web of Science ®Google Scholar
• UrbanowiczRA, LambJR, ToddI, et al. Altered effector function of peripheral cytotoxic cells in COPD. Respir Res. 2009;22:53. doi:10.1186/1465-9921-10-53
   Web of Science ®Google Scholar
• HodgeG, MukaroV, HolmesM, et al. Enhanced cytotoxic function of natural killer and natural killer T-like cells associated with decreased CD94 (Kp43) in the chronic obstructive pulmonary disease airway. Respirology. 2013;18(2):369–376. doi:10.1111/j.1440-1843.2012.02287.x23062183
   PubMed Web of Science ®Google Scholar
• TsaoCC, TsaoPN, ChenYG, et al. Repeated activation of lung invariant NKT cells results in Chronic Obstructive Pulmonary Disease-like symptoms. PLoS One. 2016;11(1):e0147710. doi:10.1371/journal.pone.014771026811900
   PubMed Web of Science ®Google Scholar
• EmotoM, KaufmannSH. Liver NKT cells: an account of heterogeneity. Trends Immunol. 2003;24:364–369. doi:10.1016/S1471-4906(03)00162-512860526
   PubMed Web of Science ®Google Scholar
• TangY, LiX, WangM, et al. Increased numbers of NK cells, NKT-like cells, and NK inhibitory receptors in Peripheral blood of patients with chronic obstructive disease. Clin Dev Immunol. 2013;2013:721–782.
   Google Scholar
• ZeigerRS, TranTN, ButlerRK, et al. Relationship of blood eosinophil count to exacerbations in Chronic Obstructive Pulmonary Disease. J Allergy Clin Immunol Pract. 2018;6(3):944–954. doi:10.1016/j.jaip.2017.10.00429153881
   PubMed Web of Science ®Google Scholar
• VillalobosRE, MagallanesJ, DavidwangA. Blood eosinophilia as predictor for patient outcomes in COPD exacerbations: a systematic review and meta-analysis. Thorax. 2017;71(Suppl 3):A160–A160. doi:10.1136/thoraxjnl-2016-209333.286
   Google Scholar
• BaloiraVA, PallariesSA. Chronic obstructive pulmonary disease with eosinophilia, an emerging phenotype? Arch Bronconeumol. 2016;52(4):177–178. doi:10.1016/j.arbr.2016.02.01226852358
   PubMed Web of Science ®Google Scholar
• SinghD, KolsumU, BrightlingCE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700. doi:10.1183/09031936.0016241425323230
   PubMed Web of Science ®Google Scholar
• MortazE, FolkertsG, RedegeldF. Mast cells and COPD. Pulm Pharmacol Ther. 2011;24(4):372. doi:10.1016/j.pupt.2011.03.007
   Web of Science ®Google Scholar
• SoltaniA, EweYP, LimZS, et al. Mast cells in COPD airways: relationship to bronchodilator responsiveness and angiogenesis. Eur Respir J. 2012;39(6):1361–1367. doi:10.1183/09031936.0008441122034650
   PubMed Web of Science ®Google Scholar
• GladerP, WachenfeldtKV, LöfdahlCG. Systemic CD4+ T-cell activation is correlated with FEV 1, in smokers. Respir Med. 2006;100(6):1088–1093. doi:10.1016/j.rmed.2005.09.02516246539
   PubMed Web of Science ®Google Scholar
• SienaL, GjomarkajM, ElliotJ, et al. Reduced apoptosis of CD8+ T-lymphocytes in the airways of smokers with mild/moderate COPD. Respir Med. 2011;105(10):1491–1500. doi:10.1016/j.rmed.2011.04.01421612902
   PubMed Web of Science ®Google Scholar
• SullivanAK, SimonianPL, FaltaMT, et al. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med. 2005;172:590–596. doi:10.1164/rccm.200410-1332OC15937291
   PubMed Web of Science ®Google Scholar
• WenY, ReidDW, ZhangD, et al. Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:327–334.21037956
   PubMedGoogle Scholar
• LapperreTS, PostmaDS, GosmanMME, et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax. 2006;61(2):115. doi:10.1136/thx.2005.04051916055612
   PubMed Web of Science ®Google Scholar
• GeerdinkJX, SimonsSO, PikeR, et al. Differences in systemic adaptive immunity contribute to the ‘frequent exacerbator’ COPD phenotype. Respir Res. 2016;17(1):140. doi:10.1186/s12931-016-0456-y27793198
   PubMed Web of Science ®Google Scholar
• CaramoriG, RuggeriP, DiSA, et al. Autoimmunity and COPD: clinical implications. Chest. 2018;153(6):1424–1431. doi:10.1016/j.chest.2017.10.03329126842
   PubMed Web of Science ®Google Scholar
• ChiapporiA, FolliC, BalbiF, et al. CD4+CD25 high DC 127-regulatory T-cells in COPD: smoke and drugs effect. World Allergy Organ J. 2016;9(1):5. doi:10.1186/s40413-016-0095-226904157
   PubMed Web of Science ®Google Scholar
• DuanMC, ZhangJQ, LiangY, et al. Infiltration of IL-17-producing T cells and Treg cells in a mouse model of smoke-induced emphysema. Inflammation. 2016;39(4):1334–1344. doi:10.1007/s10753-016-0365-827150336
   PubMed Web of Science ®Google Scholar
• ToczyskaI, Zwoliå„SkaE, ChcialowskiA. Influence of inhaled corticosteroids on bronchial inflammation and pulmonary function in Chronic Obstructive Pulmonary Disease with moderate obstruction. Adv Exp Med Biol. 2018;1047:41–52.29181828
   PubMed Web of Science ®Google Scholar
• SoltaniA, WaltersEH, ReidDW, et al. Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2016;22(11):2359–2367. doi:10.2147/COPD.S113176
   Google Scholar
• SohalSS, SoltaniA, ReidD, et al. A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial-mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study. Int J Chron Obstruct Pulmon Dis. 2014;27(9):533–542. doi:10.2147/COPD.S63911
   Google Scholar
• SinghR, MackayAJ, PatelAR, et al. Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir Res. 2014;15(1):1–10. doi:10.1186/s12931-014-0114-124397246
   PubMed Web of Science ®Google Scholar
• D’AnnaSE, BalbiB, CappelloF, et al. Bacterial–viral load and the immune response in stable and exacerbated COPD: significance and therapeutic prospects. Int J Chron Obstruct Pulmon Dis. 2016;11(1):445. doi:10.2147/COPD.S9339827042037
   PubMed Web of Science ®Google Scholar
• BlasiF, ManteroM, AlibertiS. Antibiotics as immunomodulant agents in COPD. Curr Opin Pharmacol. 2012;12(3):293–299. doi:10.1016/j.coph.2012.01.00622321568
   PubMed Web of Science ®Google Scholar
• GiustiM, BlasiF, IoriI, et al. Prulifloxacin vs levofloxacin for exacerbation of COPD after failure of other antibiotics. COPD. 2016;13(5):555–560. doi:10.3109/15412555.2016.115223627027547
   PubMedGoogle Scholar
• PatelA, WilsonR. Newer fluoroquinolones in the treatment of acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2012;1(3):243–250.
   Google Scholar
• BrunoA, CipollinaC, DiVS, et al. Ceftaroline modulates the innate immune and host defense responses of immunocompetent cells exposed to cigarette smoke. Toxicol Lett. 2017;279:9–15. doi:10.1016/j.toxlet.2017.07.87828720485
   PubMed Web of Science ®Google Scholar
• HeulensN, KorfH, JanssensW. Innate immune modulation in COPD: moving closer towards vitamin D therapy. J Pharmacol Exp Ther. 2015;353(2):360–368. doi:10.1124/jpet.115.22303225755208
   PubMed Web of Science ®Google Scholar
• BelEH, TenBA. New Anti-eosinophil drugs for asthma and COPD: targeting the trait! Chest. 2017;152(6):1276–1282. doi:10.1016/j.chest.2017.05.01928583618
   PubMed Web of Science ®Google Scholar